Tyra Biosciences (NASDAQ:TYRA) Price Target Cut to $30.00 by Analysts at HC Wainwright

Tyra Biosciences (NASDAQ:TYRA) had its price objective decreased by HC Wainwright from $32.00 to $30.00 in a research note issued to investors on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Tyra Biosciences’ Q4 2024 earnings at ($0.52) EPS, FY2024 earnings at ($1.59) EPS, Q1 2025 earnings at ($0.53) EPS, Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.56) EPS and FY2025 earnings at ($2.17) EPS.

A number of other equities research analysts have also commented on the company. Bank of America upgraded Tyra Biosciences from a “neutral” rating to a “buy” rating and increased their price target for the stock from $22.00 to $31.00 in a research report on Friday, October 18th. Piper Sandler initiated coverage on Tyra Biosciences in a report on Thursday, August 15th. They set an “overweight” rating and a $33.00 target price on the stock. Wedbush restated an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a research note on Friday, October 25th. Finally, Oppenheimer upped their price target on shares of Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday, September 19th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tyra Biosciences has a consensus rating of “Buy” and a consensus price target of $31.00.

Tyra Biosciences Price Performance

Shares of NASDAQ:TYRA opened at $15.74 on Monday. The stock has a market capitalization of $796.44 million, a price-to-earnings ratio of -9.78 and a beta of 1.08. The business’s fifty day moving average price is $21.51 and its two-hundred day moving average price is $19.98. Tyra Biosciences has a fifty-two week low of $10.60 and a fifty-two week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). Research analysts expect that Tyra Biosciences will post -1.56 EPS for the current fiscal year.

Insider Buying and Selling at Tyra Biosciences

In other news, CEO Todd Harris sold 10,092 shares of the company’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $24.13, for a total transaction of $243,519.96. Following the transaction, the chief executive officer now owns 1,479,528 shares of the company’s stock, valued at $35,701,010.64. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Tyra Biosciences news, Director Nina S. Kjellson sold 27,493 shares of Tyra Biosciences stock in a transaction on Friday, November 1st. The shares were sold at an average price of $16.56, for a total transaction of $455,284.08. Following the completion of the sale, the director now owns 458,506 shares of the company’s stock, valued at approximately $7,592,859.36. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Todd Harris sold 10,092 shares of the company’s stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $24.13, for a total transaction of $243,519.96. Following the sale, the chief executive officer now owns 1,479,528 shares of the company’s stock, valued at $35,701,010.64. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 101,050 shares of company stock worth $2,235,492. Insiders own 15.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in TYRA. RA Capital Management L.P. lifted its stake in Tyra Biosciences by 43.9% in the first quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock valued at $170,832,000 after buying an additional 3,180,155 shares during the period. BVF Inc. IL increased its stake in shares of Tyra Biosciences by 70.1% in the 1st quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock valued at $76,444,000 after acquiring an additional 1,921,599 shares during the last quarter. FMR LLC increased its stake in shares of Tyra Biosciences by 0.8% in the 3rd quarter. FMR LLC now owns 3,372,850 shares of the company’s stock valued at $79,296,000 after acquiring an additional 26,187 shares during the last quarter. Perceptive Advisors LLC increased its stake in shares of Tyra Biosciences by 50.5% in the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock valued at $16,108,000 after acquiring an additional 338,208 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Tyra Biosciences by 18.6% in the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock valued at $14,757,000 after acquiring an additional 140,833 shares during the period. 84.14% of the stock is currently owned by institutional investors.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.